Latisse FDA Approval History
FDA Approved: Yes (First approved December 24, 2008)
Brand name: Latisse
Generic name: bimatoprost
Dosage form: Ophthalmic Solution
Company: Allergan plc
Treatment for: Hypotrichosis of Eyelashes
Latisse (bimatoprost ophthalmic) is a prostamide indicated for the treatment of hypotrichosis (or reduced amount of hair) of the eyelashes. Growth of the eyelashes is a well documented side effect of bimatoprost which is currently approved as Lumigan for the treatment of glaucoma.
Development timeline for Latisse
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.